| Document |
Document Title |
|
WO/2017/036852A1 |
The present invention relates to novel means for regulating dystrophin expression for treating diseases in a subject, and more particularly to novel means for regulating dystrophin expression for treating dystrophin associated diseases v...
|
|
WO/2017/037719A1 |
Novel aminoglycosides, represented by Formulae la and lb, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the s...
|
|
WO/2017/037718A1 |
Novel pseudo-trisaccharide aminoglycosides, represented by Formula I, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions cont...
|
|
WO/2017/038925A1 |
The present invention addresses the problem of providing a pharmaceutical composition that has a high safety and with which the long-term stability can be ensured and the reduction in the amount of an active ingredient accompanying the o...
|
|
WO/2017/036992A1 |
The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions,such as a medicament, dietary supplement, functio...
|
|
WO/2017/038991A1 |
Provided are a composition for muscle building and a method for building muscle. The present invention pertains to a composition for muscle building, said composition comprising citrulline or a salt thereof and a branched amino acid or a...
|
|
WO/2017/035659A1 |
In one aspect, the Invention relates to methods and compositions to remove replicate genetic material, such as duplicate copy number variations (CNVs) present in genetic material using targeted endonuclease technology with one guide, suc...
|
|
WO/2017/038945A1 |
Provided is a therapeutic agent for diseases associated with the accumulation of abnormal substances in cells which contains, as an active ingredient, a substance for suppressing the expression of ERdj8, or a substance for suppressing an...
|
|
WO/2017/037567A1 |
This invention relates to a method of treating a condition or a disease associated with decreased levels or activity of frataxin, including Friedreich's ataxia, comprising administering to a subject in needthereof a therapeutically effec...
|
|
WO/2017/037717A1 |
Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are p...
|
|
WO/2017/036993A1 |
The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional foo...
|
|
WO/2017/033963A1 |
The present invention addresses the problem of providing a substance that has an effect of increasing ATP in cells, in particular, an ATP increasing agent that has an effect much stronger than the increasing effect achieved by using inos...
|
|
WO/2017/027967A1 |
The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or ass...
|
|
WO/2017/031502A1 |
The present invention relates to methods for conferring mTOR mediated physiological benefits by administering a composition having phospholipids, omega-3 fatty acids, and an antioxidant, or a krill extract to a mammal in need thereof.
|
|
WO/2017/026429A1 |
The present invention pertains to a muscle synthesis promoting agent which exhibits muscle synthesis promotion effects in a level equal to or higher than whey protein but with a lesser ingestion (administration) amount than whey protein....
|
|
WO/2017/026516A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. The present invention provides a compound having Nrf2 activation ability.
|
|
WO/2016/057658A9 |
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...
|
|
WO/2017/014120A1 |
Provided are a composition for stimulating TRPV1, a use for the composition for stimulating TRPV1, and a method for stimulating TRPV1. It was discovered that a specific cyclic dipeptide or a salt thereof has a TRPV1 stimulation effect. T...
|
|
WO/2017/013031A1 |
The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5- hydroxytryptamine B1 receptor-stimulating agent, an...
|
|
WO/2017/009491A1 |
A natural glucose transport promoting peptide comprising a glucose transport promoting fragment of a protein selected from SEQUENCE ID NO's: 1 to 6, and a composition comprising a plurality of glucose transport promoting peptides, is des...
|
|
WO/2017/009487A1 |
A topical, cosmetic or pharmaceutical, composition comprising a cosmetically or pharmaceutically effective amount of a peptide comprising an amino acid sequence of SEQUENCE ID NO.1 or a variant thereof.
|
|
WO/2017/009644A1 |
An inhibitor of a receptor tyrosine kinase, in particular selected from a compound of formula (I), (II) or (III) as defined in the specification for use in the treatment of fascioscapulohumeral dystrophy (FSHD)wherein formula (I) is exem...
|
|
WO/2017/009472A1 |
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (nota...
|
|
WO/2017/010382A1 |
The present invention provides an agent for the treatment of myotonic dystrophy having as an active ingredient at least one compound selected from the group consisting of erythromycin, clarithromycin, and azithromycin, a pharmacologicall...
|
|
WO/2017/004966A1 |
The present invention relates to a new pyrazine derivative, and preparation method and medical application thereof. The pyrazine derivative can remove a free radical, suppress calcium overload, has an effect of protecting cells, and is u...
|
|
WO/2017/004142A1 |
Provided herein are methods and compositions for the treatment of myopathies.
|
|
WO/2017/000869A1 |
The present invention falls within the technical field of medicines. In particular, the present invention relates to a thiazideamide derivative compound, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition...
|
|
WO/2016/207354A1 |
The present invention relates to a FGF19 polypeptide for its use as an agent increasing muscle fibers size, in the prevention and/or treatment of muscle atrophy in a mammal body.
|
|
WO/2016/208695A1 |
Disclosed is a means that can be used for modifying a biologically or pharmacologically active substance from a form incapable of permeating the blood-brain barrier to a form capable of permeating the blood-brain barrier. Also disclosed ...
|
|
WO/2016/203404A1 |
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.
|
|
WO/2016/203405A1 |
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.
|
|
WO/2016/204230A1 |
A stem cell administration method includes an administration step for injecting a stem cell-containing solution containing stem cells collected from an animal (donor animal) or subcultured stem cells obtained by subculturing the stem cel...
|
|
WO/2016/203406A1 |
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.
|
|
WO/2016/202341A1 |
The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention furth...
|
|
WO/2016/199878A1 |
Provided is a sigma-receptor binding agent that is characterized by containing an alkyl ether derivative represented by general formula [1] or a salt thereof. (In the formula, R1 and R2 are the same or different and indicate a hydrogen a...
|
|
WO/2016/197980A1 |
The present invention relates to the technical field of pharmaceutical chemistry, especially to Baicalin crystal form A, and preparation method and application thereof. The crystal form shows characteristic peaks at X-ray powder diffract...
|
|
WO/2016/197945A1 |
The present invention relates to the use of a composition for preparing a medicament for the treatment of amyotrophic lateral sclerosis and associated disorders. The composition comprises 3-methyl-1-phenyl-2-pyrazoline-5-one or pharmaceu...
|
|
WO/2016/192657A1 |
The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisom...
|
|
WO/2016/196350A1 |
The present invention relates to compositions (e.g., AUFl encoding compositions) for muscle cell uptake, satellite cell populations and compositions containing muscle satellite cell populations, pharmaceutical compositions, methods of pr...
|
|
WO/2016/195074A1 |
A read-through therapeutic containing a lincomycin compound as an active ingredient.
|
|
WO/2016/195493A1 |
Title: Means and methods for treating facioscapulohumeral muscular dystrophy (FSHD). The invention is related to facioscapulohumeral muscular dystrophy (FSHD) and in particular therapeutic means and methods for the treatment of the disea...
|
|
WO/2016/190774A1 |
Point changes to the 3'UTR nucleotide sequence of the VEGF gene which significantly increase the lifespan of the mRNA transcription product of said gene in mammalian cells have been identified. A gene construct with an optimal list of th...
|
|
WO/2016/187682A1 |
The present invention relates to a composition based on a mixture of standardised extracts or essential oils of Pterodon pubescens Benth. and Cordia verbenacea DC. Also disclosed are the use thereof and formulations comprising said compo...
|
|
WO/2016/184832A1 |
The present invention provides compounds of formula (I) wherein A, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the comp...
|
|
WO/2016/181394A1 |
The present invention discloses a composition comprising cannabis natural extract, or synthetic cannabinoids, for use in treating a subject suffering from fibromyalgia. The present invention further discloses methods and uses of the afor...
|
|
WO/2016/175136A1 |
The present invention addresses the problem of providing: a novel composition for suppressing muscular fatty change, which contains a component that can be ingested safely for a long period; and others. It is found that quercetin or a gl...
|
|
WO/2016/169028A1 |
The present invention provides three novel conotoxin peptides, namely κ-CPTx-btl06, κ-CPTx-btl07 and κ-CPTx-btl08, amino acid sequences thereof being shown as SEQ ID NO: 1, 2 and 3 respectively. The present invention also relates to p...
|
|
WO/2016/172224A1 |
An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding ...
|
|
WO/2016/171249A1 |
Provided is the compound represented by formula (I) (in the formula, Y1 is O or the like; Z1 is, C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently hydrogen atoms or the like; R1 is a s...
|
|
WO/2016/170353A1 |
(3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro
-5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.
|
